Untitled

doi:10.26655/jmchemsci.2023.2.1

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These estimates are possibly underestimated due to lack of uniform screening for early SSc for ILD [ 73 ]. The prevalence of progressive pulmonary fibrosis (PPF) among patients with SSc-ILD varies by patient population, but studies report that approximately 27–39% of SSc-ILD cases can be classified as PPF [ 74 , 75 ].…”

Section: Role Of Atx and Lpar1 Signalling In Fibrotic Diseasesmentioning

confidence: 99%

Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis

Volkmann,

Denton,

Kolb

et al. 2024

Eur Respir Rev

View full text Add to dashboard Cite

Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbidity and mortality despite current treatment options. The LPA-producing enzyme autotaxin (ATX) and LPAR1 activation contribute to inflammation and mechanisms underlying fibrosis in preclinical fibrotic models. Additionally, elevated levels of LPA have been detected in bronchoalveolar lavage fluid from patients with IPF and in serum from patients with SSc. Thus, ATX and LPAR1 have gained considerable interest as pharmaceutical targets to combat fibrotic disease and inhibitors of these targets have been investigated in clinical trials for IPF and SSc. The goals of this review are to summarise the current literature on ATX and LPAR1 signalling in pulmonary fibrosis and to help differentiate the novel inhibitors in development. The mechanisms of action of ATX and LPAR1 inhibitors are described and preclinical studies and clinical trials of these agents are outlined. Because of their contribution to numerous physiologic events underlying fibrotic disease, ATX and LPAR1 inhibition presents a promising therapeutic strategy for IPF, SSc and other fibrotic diseases that may fulfil unmet needs of the current standard of care.

show abstract

Section: Role Of Atx and Lpar1 Signalling In Fibrotic Diseasesmentioning

confidence: 99%